Background: -catenin mediates a wide variety of cellular processes, but the signaling pathways regulating -catenin downstream events are not fully understood. Role of MLK3 in modulating -catenin pathway has not been reported earlier.
The Wnt/-catenin signaling pathway has been extensively studied in the recent years due to its diverse and important roles in regulating tumorigenesis (1), (2) , development (3), (4) as well as stem cell renewal (5), (6) . In cells -catenin mediates two major functions: one in the formation of adherens junctions via its interaction with the cell adhesion molecules of the cadherin family (7) ; and second as part of Wnt-signaling pathway via its interaction with TCF/LEF family of transcription factors (1). Central to the Wnt/-catenin or canonical Wnt signaling pathway is the control of the stability of -catenin. In the absence of Wnt signaling free cytoplasmic -catenin is maintained at very low levels where it is being targeted to a phosphorylation-mediated degradation pathway that involve GSK3 (Glycogen Synthase Kinase-3), Axin and APC (Adenomatous Polyposis coli) (8) , (9) . In the presence of Wnt ligands, -catenin degradation complex is destabilized and -catenin is stabilized via mechanisms that also involve phosphorylation of LRP5/6 and recruitment of Axin to LRP (10) . Stabilized free -catenin then translocates to the nucleus, interacts with TCF/LEF family of transcription factors and activates transcription of target genes (11) . The list of -catenin/TCF target genes includes cyclin D1, c-myc, c-Jun, and is still emerging, each of which in turn promotes various cellular events (12) . Interestingly, nuclear localization and interaction of -catenin with LEF-1 are not sufficient for activating TCF-mediated transcription (13) , suggesting that additional signaling mechanisms exist to modulate the transcriptional activity of this complex. Extensive information is available in the literature regarding the signaling pathways that regulate stabilization or degradation of -catenin, however, very little is known regarding those that regulate -catenin/TCF-mediated target gene transcription.
The Serine/Threonine kinase Mixed Lineage Kinase 3 (MLK3) is a ubiquitously expressed kinase and belongs to the larger family of MLKs. In mammalian cells, MLK3 functions as a MAP3K (14), (15) , and is linked closely with the activation of JNK and its downstream c-Jun transcription factors, as well as other MAPK pathways (16) . A prominent role of MLK3 in regulating neuronal cell apoptosis is now well established, and is believed to involve downstream JNK signaling (17) . In addition, recent studies have demonstrated the expression of MLK3 in cancer cells, and established its involvement in mediating various pro-oncogenic pathways (18) , (19) . A crosstalk of Wnt/-catenin signaling pathway with another closely linked mammalian MAP3K member TAK1 (TGF-activated kinase1) has been reported recently, where TAK1 negatively regulates Wnt/-catenin pathway (20) . This is accomplished by phosphorylation of TCFs by TAK1 downstream kinase NLK (Nemo-like kinase) resulting in an inhibition of -catenin/TCF DNA binding and thus
-catenin/TCF
transcriptional activity. Interestingly, Wnt pathway can in turn activates TAK1/NLK cascade (21) , and thus the TAK1-NLK axis might represent a physiological mechanism by which Wnt/-catenin signaling is terminated in normal cells. It thus seems that MAP3Ks can antagonize the canonical Wnt/-catenin pathway, but the mechanisms involved are still not clear. In order to elucidate further the details of -catenin pathway and to understand whether other MAP3Ks might be involved in -catenin regulation, we designed studies in various cell types to determine the effect of MLK3 on -catenin expression and -catenin/TCF signaling. Our studies indicated that MLK3 can induce the expression of -catenin in a variety of cancer cells including prostate cancer cells, an effect that requires the kinase activity of MLK3. Intense -catenin expression is detected by Immunofluorescence analysis when co-transfected with MLK3-WT, associated with increased localization in the nucleus and membrane ruffles. This is achieved via post-translational stabilization of -catenin independent of GSK3. Surprisingly, despite increasing -catenin expression, MLK3 antagonized -catenin/TCF transcriptional activity, suggesting an inhibitory effect of MLK3 on canonical Wnt-pathway. This decrease in -catenin/TCF transcriptional activity was not due to reduced interaction between -catenin and TCF4, but was associated with an increased interaction between -catenin and KLF4. In addition, coexpression of MLK3-WT and -catenin resulted in cell cycle arrest at G2/M phase.
EXPERIMENTAL PROCEDURES:
Reagents: DMEM, LipofectAMINE 2000 and
-
Galactosidase assay kit were purchased from Invitrogen (Carlsbad, CA); the luciferase assay kit was from Promega (Madison, WI) and formaldehyde from Polysciences (Warrington, PA). The antibodies utilized were obtained from the following sources: total MLK3 (Epitomics, Burlingame, CA), GAPDH (Ambion, Austin, TX), HA.11 (Covance, Berkeley, CA), -actin, rabbit anti-HA and M2 (anti-Flag) (Sigma Aldrich Corporation, St. Louis, MO), 9E10 (anti myc) (Roche Applied Science, Indianapolis, IA), -catenin (BD Bioscience, San Jose, CA), P-c-Jun, total c-Jun, phospho cdc2tyr15, total cdc2, cyclin B1, -tubulin and TCF4 (Cell Signaling Technology, Danvers, MA), KLF4 (Santa Cruz Biotechnology. Inc., Santa Cruz, CA), GST (Millipore-Upstate, Lake Placid, USA), fluorophore-conjugated donkey anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch, West Grove, PA). The JNK inhibitor SP600125 was from Alexis Biochemicals, Axxora (San Diego, CA), GSK3 inhibitors (AR-A014418 and Kenpaullone) and Cycloheximide from EMD Biosciences (Gibbstown, NJ) and Pan-MLK inhibitor CEP11004 was a gift from Cephalon. The pGL3OT luciferase vector was obtained from Dr. Bert Vogelstein (22) , the HA-tagged GSK3 expression vectors (WT, K/A and S9A) were from Dr. James R Woodgett (University of Toronto, Toronto, Canada) (23), the KLF4 vectors (WT, ΔC and ΔN) were from Dr. Wange Lu (University of Southern California, Los Angeles, CA (24), GFP--catenin was from Dr. Robert Malenka (Stanford University School of Medicine, CA) (25) and the HA-tagged -catenin vectors (WT and S37A) were obtained from Dr. Stephen Byers (26). The M2-tagged MLK3 (WT and K/A) and GST-tagged MLK3 (WT, K/A, 1-385 WT, 1-385 K/A) vectors were utilized as described elsewhere (14), (27), (17) .
Cell Culture:
Human embryonic kidney cell line (HEK-293) and human cervical cancer cell line (HeLa) were maintained in DMEM supplemented with 10% FBS, 100IU/ml penicillin and 100g/ml streptomycin. Human prostate cancer cells (LNCaP, PC3 and 22Rv1) were maintained in RPMI media supplemented with 10% FBS, 100IU/ml penicillin and 100µg/ml streptomycin. In the studies with various kinase inhibitors, cells were treated with the specific inhibitors after transfection followed by Western Blot analysis or luciferase assays.
Transient transfection and luciferase assays:
Subconfluent populations of HEK-293, HeLa, LNCaP and 22Rv1 cells were transiently transfected by various expression vectors utilizing lipofectAMINE 2000 as per manufacturer's instructions and as described previously (19) . PC3 cells were transfected utilizing AMAXA nucleofection kit V. Briefly, cells were trypsinized and 1x10 6 PC3 cells were resuspended in 100l of nucleofection solution, transferred to the nucleofection cuvettes and transfected using Amaxa nucleofector device, following the specific program T-019. Cells were recovered by adding 500µl complete pre-equilibrated media and transferred to a 6-well plate at 37 0 C. Following 48 hours of recovery in the growth medium, the transfected cells were harvested and analyzed via Western Blot analyses or luciferase assays. For the cycloheximide experiments, HeLa cells transiently transfected with the various expression vectors (or MCF-7 and MCF-7-KD cells) were treated with 50g/ml cycloheximide (CHX), following a 48 hour recovery in growth media. Cells were harvested at various lengths of time following CHX treatment and subjected to Western Blot analysis.
In these experiments, since overexpression of MLK-WT increases -catenin expression significantly, twice the amount of total protein lysates were utilized in the Western Blots of -catenin + EV (or MCF7-KD) samples compared to the -catenin + MLK3-WT (or MCF7) ones to normalize -catenin protein levels between the two sets. Luciferase assays were performed as described earlier (19) . Briefly, subconfluent cells were transfected with pGL3OT-luciferase-reporter construct (28) along with -Galactosidase vector (to correct for transfection efficiency) using lipofectAMINE 2000. Each transfection was performed in triplicate and each experiment was repeated at least twice. Luciferase and -Galactosidase (-Gal) assays were performed using a luminometer (Berthold Technologies, Centro XS 3 LB 960) and a plate reader (Power Wave XS, Biotek) respectively. The results obtained were calculated as the ratio of relative light units (RLU) to -Gal values (RLU/-Gal) and expressed as % increase compared to controls.
Small interference RNA (siRNA): MLK3 siRNA (sense 5'-GGGCAGUGACGUCUGGAGUUUdTdT-3' and the corresponding antisense) (19) were synthesized from Dharmacon (Lafayette, CO). The control-siRNA was from Ambion (Austin, TX). siRNA transfection was performed using lipofectAMINE 2000 as per manufacturer's instructions following protocols described earlier (29). The MCF7 and ZR75-1 cells with stable MLK3 knockdown were created by utilizing validated MLK3-shRNA in lentiviral vector pLKO.1-Puro (Sigma, St. Louis, MO) utilizing standard lentiviral procedures. MLK3-shRNA expressing cells were selected with puromycin (100g/ml) and propagated, and knockdown of MLK3 expression was confirmed by PCR using validated primers (data not shown) and Western Blot analysis (see Fig 1E) .
Reverse-Transcription (RT)-PCR analysis:
Total RNA was extracted from cells using the RNAqueous®-4PCR Kit (Ambion, TX). 500ng of total RNA was subjected to reverse-transcription (RT) reaction using the random primer and reverse transcriptase (Promega, Madison, WI). Total gene expression was then analyzed by semiquantitative polymerase chain reaction (PCR), using highfidelity PCR system (Eppendorf, Mastercycler gradient, Hauppauge, NY). The following primers were used and obtained from (IDT, San Diego,CA): 
Western Blot analysis:
Western Blot analysis was performed utilizing procedures described previously (30). Briefly, equal amounts of total cell extracts or immunoprecipitated samples were fractionated by SDS-PAGE, transferred to PVDF membranes, and subjected to Western Blot analysis utilizing various antibodies. To determine changes in -catenin localization biochemically, detergent fractionation was carried out as follows. Cell pellets were sonicated briefly (~10 secs) in 50 mM Tris-HCl buffer, pH 7.5 containing protease inhibitors followed by centrifugation at 350,000 x g for 15 minutes (ultracentrifugation). The supernatant was isolated and termed Tris soluble fraction (or Tris) and the pellet was subjected to similar extraction and centrifugation with various detergents (in Tris-HCl buffer) in the following sequence: 1% Triton X-100 (Triton-X fraction), 1% Sarkosyl (Sarkosyl fraction) and 2% SDS (SDS fraction). Tris fraction containing equal amounts of total protein along with equal volumes of Triton-X, Sarkosyl and SDS fractions (equivalent to Tris fraction) were then analyzed by SDS-PAGE.
Immunofluorescence Microscopy:
HeLa cells transfected with the indicated expression constructs using LipofectAMINE 2000 were allowed to adhere to fibronectin-treated glass coverslips and fixed with 3.7% formaldehyde in 0.1 M Pipes, pH 6.8 48 hours following transfection. The following primary antibodies were utilized: mouse α-myc antibody, rabbit α-HA antibody, which were secondarily labeled with fluorophore-conjugated donkey anti-mouse or anti-rabbit antibodies. They were also stained with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) to show the nucleus. Images were collected on a DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP HQ; Photometrics) using a 60 × NA 1.42 objective lens and were deconvolved with SoftWoRx deconvolution software (Applied Precision).
Immunoprecipitation and kinase assay:
Immunoprecipitation (IP) and GST pull-down experiments by either specific antibodies or GSH beads respectively were carried out as described (31). The Immunoprecipitates were washed thoroughly and then processed for Immunoblotting with antibodies against various interacting proteins or subjected to in vitro kinase assay, in the presence of [32P]-ATP and GST--catenin as MLK3 substrate (28). In some experiments the samples were pretreated with either 400nM CEP11004 or 40nM SP600125 for 30 minutes before subjecting to kinase assay. These samples were then fractionated by SDS-PAGE and 32 P incorporation in -catenin was quantified using a Phospho Imager (STORM 820, GE Healthcare Bio-sciences, USA).
Cell Cycle Analysis:
HeLa cells transfected with various GFP-tagged vectors were fixed overnight at 4 0 C in Fixing solution (containing 15% FBS and 15% PBS in 70% ethanol). Following 2 washes in cold PBS, they were incubated for 1 hour at room temperature in Propidium Iodide (PI) solution containing 0.05mg/ml PI, 0.1mM EDTA, 0.05mg/ml RNase A in PBS before analyzing by flow cytometry. The percentage of cells in various stages of cell cycle in GFP positive and GFP negative populations were determined using FACSCanto II (BD, San Jose CA) and analyzed by FlowJo 7.5.5 (TreeStar Ashland OR). For Western Blot analyses, cells were transfected similarly and ~2x10 6 GFP-positive and GFPnegative cells were sorted utilizing FACSAria (BD, San Jose CA) and analyzed by SDS-PAGE.
RESULTS:

MLK3 regulates -catenin expression in various cell types:
To delineate the signaling molecules that can regulate -catenin function, we focused on the MAP3K member MLK3 which is known to regulate various cellular pathways (18), (19) . Subconfluent populations of human cell lines derived from embryonic kidney (HEK-293) and cervical carcinoma (HeLa) were transfected separately with either HA-epitope tagged -catenin alone or in combination with M2-tagged MLK3 wild type (WT) or kinase dead (K/A) forms. Western Blot analysis performed with antibodies against the HA-tag showed a distinct induction of HA--catenin expression in both the cell types ( Fig 1A & Supplemental Fig1A , HA panel, lane 3). To rule out any non specific artifacts of overexpression, these studies were also performed with myc-epitope tagged -catenin and GST-tagged MLK3, which showed an MLK3-mediated induction of -catenin expression ( Fig  1B, lane 3) . In these studies, MLK3-mediated induction of -catenin required the kinase activity of MLK3, since MLK3-K/A (kinase dead) was unable to induce -catenin expression ( To determine whether MLK3 can regulate endogenous -catenin expression, endogenous MLK3 expression was knocked down in HeLa cells using MLK3-siRNA as described earlier (19) . The results shown in Fig 1D indicate a time dependent decrease in MLK3 expression with MLK3-siRNA and not with control-siRNA (compare lanes 1&2 and 3&4, MLK3 panel). Knockdown of MLK3 expression also results in a corresponding decrease in endogenous -catenin expression (-catenin panel). In addition, two breast cancer cell lines (MCF-7 and ZR75-1) generated with stable overexpression of MLK3-shRNA showed a significant decrease in endogenous -catenin expression (Fig 1E, compare lanes 1&2 and 3&4). This was parallel to the reduced expression of endogenous MLK3 in the both cell types overexpressing MLK3-shRNA. These novel observations suggested that kinase active MLK3 can induce expression of -catenin in various cell types, and might be modulating -catenin downstream events.
MLK3 regulates -catenin expression and localization:
Since -catenin can be localized in various cellular compartments, Immunofluorescence studies were performed to detect any changes in -catenin localization following co-expression with MLK3. Coexpression of -catenin with MLK3-K/A (Fig  2A, HA panel, column 3) did not alter the level of -catenin when compared to -catenin alone (column 2). However, when co-expressed with MLK3-WT, the expression of -catenin was significantly enhanced, such that it was impossible to determine the localization changes using the same exposure times and display settings (column 4). When cells expressing -catenin and MLK3-WT were viewed with display settings appropriate for their expression levels, -catenin could be observed to localize both in the plasma membrane and in the nucleus (Fig 2B, see HA) . Both -catenin and MLK3-WT localized in similar areas of the plasma membrane which appear to be membrane ruffles or areas of dynamic membrane activity (see merge). Importantly, MLK3-WT expression also seemed to be induced when transfected with HA--catenin (Fig 2A, myc panel, compare columns 1 and 4). To confirm these results biochemically, cells were fractionated by sequential extraction in Tris-HCl buffer followed by Triton X-100, Sarkosyl and SDS. These results showed that myc--catenin when expressed alone, is mostly enriched in the cytoplasmic or Tris fraction (see Supplemental Fig 2 , myc--catenin, panel D, lane 5). However, in the presence of MLK3-WT it is significantly enriched in the SDS fraction, which is expected to be the most insoluble compartment (myc--catenin, panel L, lane 16). The same profile was detected with anti -catenin antibody (compare -cat ectopic, L panel lane 16) , whereas the endogenous -catenin was extracted mostly in the Triton X fraction, which is where membrane-bound proteins are concentrated (see -cat endogenous). These studies indicate that MLK3-WT regulates -catenin expression and localization.
MLK3 can interact with -catenin independent of its kinase activity:
In order to obtain a better understanding of how MLK3 might be modulating -catenin pathway, we determined whether they interacted with each other. Immunoprecipitation of endogenous MLK3 showed interaction with endogenous -catenin and vice versa ( Fig  3A) . 4) . This suggested that MLK3 and -catenin can interact with each other in vivo and this interaction is independent of MLK3 kinase activity.
MLK3 can phosphorylate -catenin in vitro:
Since MLK3-mediated induction of -catenin expression required the kinase activity of MLK3 (Fig 1A-1C) , we determined whether MLK3 was capable of phosphorylating -catenin in vitro. To achieve this, M2-tagged MLK3-WT or K/A were transfected in HEK-293 cells. To avoid any confusion in detecting co-migrating phospho--catenin and phospho-MLK3 bands (due to MLK3 autophosphoryation) following kinase assay, cells were separately transfected with a truncated active GST-tagged MLK3 (1-385)-WT and K/A vector. In vitro kinase assays were then performed with immunoprecipitated ectopic MLK3 (by antibodies against M2 tag or GST tag) utilizing GST--catenin as a substrate as described previously (28 (Fig 4C) . However, overexpression of MLK3-WT resulted in a significant stabilization of the protein without significant decay until 12 hours (Fig 4B & C) , suggesting that MLK3 increased -catenin expression via post-translational modification. To determine whether MLK3 also regulated endogenous -catenin similarly, cycloheximide experiments were performed with MCF7 and MCF-7KD (with stable knockdown of MLK3) cells. These results also showed faster decay of endogenous -catenin protein in the MCF-7KD cells compared to the MCF-7 cells (Fig 4D) .
MLK3 regulates -catenin protein stability independent of GSK3:
The next sets of studies were designed to understand any participation of GSK3 in MLK3-induced stabilization of -catenin, since GSK3 is known to regulate -catenin degradation (32 Fig 5C. Combined together, these results suggested that MLK3-induced stabilization of -catenin is independent of GSK3.
MLK3 inhibits -catenin and TCF-mediated transcriptional activity:
To determine whether MLK3-mediated induction of -catenin expression also resulted in activation of -catenin/TCF-dependent transcription (conventional Wnt-signaling pathway), HeLa cells were transfected with a TCF-responsive reporter pGL3OT (with wild-type TCF sites) as described elsewhere (28). Overexpression of -catenin-WT alone resulted in significant induction of pGL3OT luciferase activity (Fig 6A, compare lanes 1 & 2) , indicative of an activation of -catenin/TCF dependent transcription. Surprisingly, overexpression of MLK3-WT resulted in a strong inhibition of this transcriptional activity, an effect that was dependent on MLK3 kinase activity (compare lanes 3 & 4) . Similarly, overexpression of increasing concentrations of MLK3 showed a concentration dependent induction of -catenin expression (Supplemental Fig 4B, myc panel) , but a corresponding reduction of TCF-transcriptional activity (Supplemental Fig 4A) . In addition PCR analyses showed an MLK3-mediated reduction of myc and Survivin mRNA expression, the two downstream targets of conventional -catenin/TCF pathway (Fig 6C) . These results suggested that MLK3 activation leads to an antagonism of the conventional -catenin/TCF dependent transcription in cancer cells, despite a stabilization of -catenin protein. . In order to determine whether these proteins also interacted with MLK3, the TCF4 and KLF4 immunoprecipitates were immunoblotted with antibodies against MLK3. These showed that both WT and K/A MLK3 were capable of interacting with TCF4 (Fig 7A, lanes 4 & 5, IB: MLK3) as well as with KLF4 (Fig 7B,  lanes 4 & 5, IB: MLK3 ). In addition, Immunoprecipitation of endogenous TCF4 and KLF4 showed interaction with endogenous MLK3 (Fig 7E) . These results indicated that MLK3 does not effect -catenin/TCF interaction and likely antagonize TCF transcriptional activity via recruiting KLF4 repressor to this complex.
Effect of MLK3 on
To confirm the participation of KLF4 in these, the effect of MLK3 on -catenin/TCF responsive luciferase activity was estimated in the presence of KLF4 (WT and ΔN and ΔC-mutants). These 2 mutants of KLF4 in earlier studies were unable to inhibit -catenin/TCF-mediated transcriptional activity (34) and ΔC served as a dominant negative KLF4 mutant (35). Overexpression of WT-KLF4 synergized with MLK3-WT to inhibit TCF luciferase activity ( Fig  6B, compare lanes 3 & 4) . However, the two mutants of KLF4 (ΔN and particularly ΔC), completely abolished MLK3-mediated antagonism of TCF luciferase activity (lanes 5 & 6), suggesting the participation of KLF4 in this.
MLK3 modulates -catenin pathway in prostate cancer cells:
Earlier studies by different groups have shown involvement of -catenin pathway in prostate cancer (36). In order to determine whether MLK3 can modulate -catenin pathway in prostate cancer cells, MLK3 and -catenin studies were designed with androgen sensitive (LNCaP, 22Rv1) and androgen insensitive (PC3) prostate cancer cells. Overexpression of MLK3-WT and not K/A was capable of inducing the expression of -catenin in all the cell types tested (Fig 8A, B , C and Supplemental Fig 1B) , suggesting that MLK3-induced expression of -catenin is a generalized event. The fact that both androgen sensitive (LNCaP) and insensitive (PC3) cells showed similar effects suggested that this stabilization operates in prostate cancer cells independent of the androgen receptor expression. In addition, MLK3- 
MLK3-WT and -catenin co-expression regulates cell cycle progression:
The results described above suggested the involvement of a novel pathway by which MLK3 regulated -catenin expression and transcriptional activity. In order to determine the cellular effects of MLK3 and -catenin coexpression in cancer cells, GFP-tagged MLK3 and -catenin were overexpressed in HeLa cells and cell cycle profile was analyzed in GFP positive and GFP negative cells. These results showed a significant increase in G2/M cell population and a corresponding decrease in G0/G1 population following coexpression of MLK3-WT and -catenin in the GFP positive cells (Fig 9A & B) . This cell cycle profile in GFP negative cells (used as negative control) didn't show any significant change following overexpression of these two proteins (Supplemental Fig 5A & B) . Western Blot analysis of these samples indicated a reduction of total Cdc2 expression associated with a modest increase in cyclin B1 levels specifically in the GFP positive MLK3-WT and -catenin overexpressing cells (Fig 9C and Supplemental Fig 5C, lane 3) . Taken together, these suggested that MLK3 can modulate the expression of -catenin and -catenin/TCFmediated transcriptional activity in cancer cells, ultimately leading to cell cycle arrest.
DISCUSSION:
In summary, our results showed that overexpression of MLK3 can induce expression of -catenin in various cell types including prostate cancer cells. This involves a post-translational stabilization of catenin protein. The levels of -catenin in the normal cells are strictly regulated by a degradation complex that involves GSK3-APCAxin (8). Since MLK3 is also known to have crosstalk with GSK3 signaling (17) , it was conceivable that MLK3-induced stabilization of -catenin was achieved via targeting members of the -catenin degradation complex (namely GSK3). Although the detailed mechanism how MLK3 stabilizes -catenin is still unclear, it seems to be independent of GSK3 pathway. This is evident from GSK3 overexpression studies and those with two different GSK3 inhibitors (AR-A014418 and Kenpaullone). Furthermore, MLK3 was able to induce the expression of the GSK3 phosphorylation deficient -catenin (S37A) mutant ( Fig 5C) . It is unclear at this time whether MLK3 targets members of the other non-conventional pathways of -catenin degradation for regulating -catenin expression (28), (37). The effect of MLK3 on -catenin stabilization required the kinase activity of MLK3, since a kinase dead (K/A) mutant or pretreatment with pan MLK inhibitor (CEP11004) were unable to show this stabilization. MLK3 was however, capable of interacting with -catenin independent of its kinase activity and also induced -catenin phosphorylation in vitro. Identification of the specific MLK3 phosphorylation site(s) on -catenin in the future will be critical in determining their involvement in -catenin stabilization, -catenin/TCF transcriptional activity and downstream cellular effects.
Our results also showed that despite increasing -catenin expression, MLK3 inhibited -catenin/TCF-mediated transcription and antagonized expression of -catenin target genes. This novel observation suggested that overexpression or stabilization of -catenin is not sufficient to activate -catenin/TCF-dependent transcription. This is supported by earlier studies which showed that nuclear localization and interaction of -catenin with LEF-1 are still not enough to activate TCF-mediated transcription (13) . In addition, overexpression of an oncogenic form of -catenin in the liver was unable to show induction of -catenin/TCF target genes cyclin D1 and c-myc (38). It is thus likely that once -catenin is stabilized and complexed with TCF, it needs additional signaling modification to be able to induce optimal TCF-responsive transcription, which can be achieved via recruitment of coactivators and corepressors. In fact, -catenin/TCF transcriptional activity is induced following recruitment of coactivators such as CREB binding protein (CBP) (39) and CARM1 (40). Our immunoprecipitation studies with endogenous TCF4 showed no decrease in its interaction with -catenin in the presence of MLK3 while transcriptional activity is repressed. These results suggested that MLK3 does not regulate -catenin/TCF-mediated transcription via inhibiting -catenin and TCF interaction, but might be modulating this complex further downstream. One possible mechanism for this might be the recruitment of a repressor to the -catenin/TCF complex. Recently, a cross-talk between Kruppellike factor 4 (KLF4) and -catenin has been reported (35), where KLF4 inhibits -catenin/TCF transcriptional activity in a manner that does not interfere with -catenin/TCF interaction, but interferes with coactivator recruitment to -catenin (41). Interestingly, our immunoprecipitation studies demonstrated increased interaction between KLF4 and -catenin following MLK3 overexpression, and indicate this as a potential mechanism mediating this transcriptional repression. In fact, overexpression of KLF4 ΔC (known to function as dominant negative mutant for -catenin/TCF pathway (35) abolished MLK3-induced repression of -cat/TCF-responsive transcription. In addition KLF4 was shown to interact with MLK3 and might undergo additional post-translational modification for its recruitment to -catenin.
An understanding of the cellular effects that are mediated via MLK3/-catenin axis is necessary to understand how upstream signaling pathways regulate diverse -catenin functions. These will also explain why overexpression of -catenin mediates tumorigenic pathways differentially in various tissues (42), (38), (43). In our studies, overexpression of MLK3-WT and -catenin in combination resulted in attenuation of cell cycle progression at G2/M phase. Although -catenin overexpression has been linked with a G2 arrest and subsequent apoptosis in earlier studies (44), our results provide the first clue regarding the signaling pathway that targets -catenin towards this. It will be of interest to determine whether this signaling mechanism is also responsible for other cellular functions mediated by -catenin (45). The detailed mechanism how this growth arrest is achieved is still unclear, although our Western data with GFP positive cells indicate changes in total cdc2 and cyclin B1 expression in the arrested cells. More in depth studies are needed to confirm their participation.
MLK3 expression has been shown in breast cancer (18) , gastric cancer (19) (48), (49) . In addition, -catenin can interact with and augment transcriptional function of androgen receptor in a ligand dependent manner (50), (51) . Understanding of the upstream signaling mechanism(s) which regulate -catenin pathway in prostate cancer cells is thus critically important. Our results demonstrate for the first time that MLK3 can regulate -catenin expression and -catenin/TCF activation in prostate cancer cells. Since this causes an inhibition of -catenin/TCF transcriptional activation, activating MLK3 might be an effective means of antagonizing aberrant Wnt-signaling in those cancers that have activating -catenin mutations. This is supported by the fact that in 22Rv1 cells which has functional Wnt/ -catenin signaling (46), overexpression of MLK3-WT can reduce the expression of -catenin downstream cyclin D1 (Fig 8F) . In addition, MLK3-induced -catenin expression seemed to be functional in both androgen sensitive (LNCaP, 22Rv1) as well as insensitive (PC3) cells, suggesting that MLK3-based therapy might be effective in the androgenresistant and more aggressive forms of prostate cancer. 4) . In E a stabilized mutant form of -catenin (S37A) was co-transfected either alone (lane 2) or with increasing concentration of MLK3-WT (lanes 3 & 4) . Luciferase and -Gal assays were performed as in 6A. (F) 22Rv1 cells were transfected with the indicated plasmids and following a recovery in growth medium, they were harvested and analyzed by Western Blots. 
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